低外径覆膜支架治疗胸主动脉瘤与溃疡病变的一年结果
这项前瞻性、国际、非盲、非随机关键性试验在美日36个中心纳入110例降胸主动脉瘤或穿透性动脉粥样硬化性溃疡患者,评估第二代低外径RelayPro胸主动脉覆膜支架的安全性和有效性。30天主要不良事件复合率为6.4%(95%置信区间上限11.6%,P=0.0002),1年主要有效性为89.2%(95%置信区间下限81.8%,P=0.0185),两个主要终点均达到预设性能目标。
要点
- 30天主要不良事件复合率6.4%,95%置信区间上限11.6%,P=0.0002,达到主要安全终点。
- 1年治疗成功率89.2%,95%置信区间下限81.8%,P=0.0185,达到主要有效性终点。
- 技术成功率100%,无支架移植物闭塞、破裂、断裂或移位,随访仍在进行以评估长期耐久性。
核心结论
- 低外径RelayPro胸主动脉覆膜支架达到研究主要终点,在降胸主动脉瘤或穿透性动脉粥样硬化性溃疡患者中显示满意的30天安全性和1年有效性,随访仍在进行以评估长期结局和耐久性。
研究设计与样本
- 前瞻性、国际、非盲、非随机关键性试验,在美国和日本36个中心于2017年至2019年入组110例患者。
- 主要安全终点为30天主要不良事件(死亡、心肌梗死、卒中、肾/呼吸衰竭、瘫痪、肠缺血、术中失血),主要有效性终点为1年治疗成功(技术成功、通畅、无动脉瘤破裂、I/III型内漏、支架断裂、再干预、动脉瘤扩张和移位),与上一代Relay关键性研究的性能目标比较。
主要发现
- 研究人群110例,中位(四分位距)年龄76(70-81)岁,男性69例(62.7%),亚洲人43例(39.1%)。
- 治疗 fusiform 动脉瘤76例(69%)、囊状动脉瘤24例(22%)、穿透性动脉粥样硬化性溃疡10例(9%);82.7%的患者使用非裸支架配置。
- 技术成功率为100%;中位(四分位距)手术时间91(64-131)分钟,释放时间16(10-25)分钟。
- 美国队列50例患者(73.5%)经皮入路,日本中心仅使用外科切开。
- 30天复合主要不良事件率为6.4%(95%置信区间上限11.6%,P=0.0002):2例卒中、2例术中失血超过1000 mL需输血、2例瘫痪事件、1例肾衰竭。
局限性
- 原文在结论中写明随访仍在进行以评估长期结局和耐久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study objective was to evaluate the safety and effectiveness of the second-generation, low-profile RelayPro (Terumo Aortic) thoracic endograft for the treatment of descending thoracic aortic aneurysm or penetrating atherosclerotic ulcer. METHOD: A prospective, international, nonblinded, nonrandomized, pivotal trial analyzed a primary safety end point of major adverse events at 30 days (death, myocardial infarction, stroke, renal/respiratory failure, paralysis, bowel ischemia, procedural blood loss) and a primary effectiveness end point of treatment success at 1 year (technical success, patency, absence of aneurysm rupture, type I/III endoleaks, stent fractures, reinterventions, aneurysm expansion, and migration) compared with performance goals from the previous generation Relay pivotal study. The study was conducted in 36 centers in the United States and Japan and enrolled participants between 2017 and 2019. RESULTS: The study population of 110 patients had a median (interquartile range) age of 76 (70-81) years, 69 (62.7%) were male, and 43 (39.1%) were Asian. Patients were treated for 76 fusiform aneurysms (69%), 24 saccular aneurysms (22%), and 10 penetrating atherosclerotic ulcers (9%). Most patients (82.7%) were treated with a non-bare stent configuration. Technical success was 100%. The median (interquartile range) procedure time was 91 (64-131) minutes, and the deployment time was 16 (10-25) minutes. A total of 50 patients (73.5%) in the US cohort had percutaneous access, whereas centers in Japan used only surgical cutdown. The 30-day composite major adverse events rate was 6.4% (95% upper confidence interval, 11.6%; P = .0002): 2 strokes, 2 procedural blood losses greater than 1000 mL requiring transfusion, 2 paralysis events, and 1 renal failure. Primary effectiveness was 89.2% (lower 95% confidence interval, 81.8%; P = .0185). Nine subjects experienced 11 events (1 aneurysm expansion, 6 secondary interventions, and 4 type I endoleaks). There was no loss of stent-graft patency, no rupture, no fractures, and no migration. CONCLUSIONS: The low-profile RelayPro thoracic endograft met the study primary end points and demonstrated satisfactory 30-day safety and 1-year effectiveness for the treatment of patients with aneurysms of the descending thoracic aorta or penetrating atherosclerotic ulcers. Follow-up is ongoing to evaluate longer-term outcomes and durability.
引用
- Szeto WY, Vallabhajosyula P, Matsuda H, et al. One-year results with a low-profile endograft in subjects with thoracic aortic aneurysm and ulcer pathologies. J Thorac Cardiovasc Surg. 2022. PMID: 35241276. doi:10.1016/j.jtcvs.2021.10.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。